NEW YORK, March 15, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600:
Following is a summary of the changes that will take place prior to the open of trading on the effective date:
Effective Date | Index Name | Action | Company Name | Ticker | GICS Sector | |
March 21, 2023 | S&P SmallCap 600 | Addition | CVR Energy | CVI | Energy | |
S&P SmallCap 600 | Deletion | Atlas Air Worldwide Holdings | AAWW | Industrials | ||
March 22, 2023 | S&P MidCap 400 | Addition | Exponent | EXPO | Industrials | |
S&P MidCap 400 | Deletion | IAA | IAA | Industrials | ||
S&P SmallCap 600 | Addition | Certara | CERT | Health Care | ||
S&P SmallCap 600 | Deletion | Exponent | EXPO | Industrials | ||
For more information about S&P Dow Jones Indices, please visit www.spdji.com
ABOUT S&P DOW JONES INDICES
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.
S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.
FOR MORE INFORMATION:
S&P Dow Jones Indices
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$11.02 |
Daily Change: | 0.05 0.46 |
Daily Volume: | 1,148,777 |
Market Cap: | US$1.770B |
August 06, 2025 August 04, 2025 July 31, 2025 May 05, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load